Evaluation of Temozolomide in Patients with Myelodysplastic Syndrome

Reference

• Au!, C., Gattermann, N. and Schneider, W. (1995) "Epidemiolo-gical and etiological aspects of myelodysplastic syndromes", Leukemia Lymphoma, 16, 247–262.
   PubMed Web of Science ®Google Scholar
• Molldrem, ii., Caples, M., Mavroudis, D., Plante, M., Young, N.S. and Barrett, A.J. (1997) "Antithymocyte globulin for patients with myelodysplastic syndrome", Br. J. Haematol., 99, 699–705.
   Web of Science ®Google Scholar
• De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., etal. (1995) "Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia following MDS of more than 6 months duration", Leukemia, 9, 1805 — 1811.
   Google Scholar
• Oosterveld, M., Muus, P., Suciu, S., Koller, C., Verhoef, G., Labar, B., et al. EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center (2002) "Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors", Leukemia, 16, 1615 — 1621.
   PubMed Web of Science ®Google Scholar
• O'Reilly, S.M., Newlands, ES., Glaser, M.G., Brampton, M., Rice-Edwards, J.M., Illingworth, R.D., et al. (1993) "Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors", Eur. J. Cancer, 29A, 940–942.
   Web of Science ®Google Scholar
• Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., et al. (1999) "Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse", J. Clin. Oncol., 17, 2762–2771.
   PubMed Web of Science ®Google Scholar
• Stevens, M.F., Hickman, J.A., Langdon, S.P., Chubb, D., Vickers, L., Stone, R., et al. (1987) "Antitumor activity and pharmacoki-netics in mice of 8-carbamoy1-3-methyl-imidazo[5,1-d]-1,2,3,5-tetra-zin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine", Cancer Res., 47, 5846 — 5852.
   Google Scholar
• Tentori, L., Graziani, G., Gilberti, S., Lacal, P.M., Bonmassar, E. and D'Atri, S. (1995) "Triazine compounds induce apoptosis in 06-alkylguanine-DNA alkyltransferase deficient leukemia cell lines", Leukemia, 9, 1888 — 1895.
   PubMed Web of Science ®Google Scholar
• Newlands, ES., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., etal. (1992) "Phase I trial of temozolomide", Br. J. Cancer, 65, 287 — 291.
   Google Scholar
• Seiter, K., Liu, D., Loughran, T., Siddiqui, A., Baskind, P. and Ahmed, T. (2002) "Phase I study of temozolomide in relapsed/ refractory acute leukemia", J. Clin. Oncol., 20, 3249 — 3253.
   Web of Science ®Google Scholar
• Bennett, J.M., Catovsky, D., Daniel, M.J., Flandrin, G., Galton, D.A., Gralnick, H.R., et al. (1982) "Proposals for the classification of the myelodysplasia syndromes", Br. J. Haematol., 51, 189–199.
   Web of Science ®Google Scholar
• National Cancer Institute. Guidelines for the Reporting of Adverse Drug Reactions, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.
   Google Scholar
• Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., et al. and World Health Organization(WHO) International Working Group (2000) "Report of an international working group to standardize response criteria for myelodysplastic syndromes", Blood, 96, 3671— 3674.
   Google Scholar
• Harris, N.L., Jaffe, ES., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., et al. (2000) "The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting —Airlie House, Virginia, November, 1997", Hematol. J., 1, 53–66.
   PubMedGoogle Scholar
• Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., et al. (1997) "International scoring system for evaluating prognosis in myelodysplastic syndromes", Blood, 89, 2079 — 2088.
   Google Scholar
• Jen, J.F., Cutler, D.L., Pai, S.M., Batra, V.K., Affrime, M.B., Zambas, D.N., et al. (2000) "Population pharmacokinetics of temozolomide in cancer patients", Pharm. Res., 17, 1284— 1289.
   Google Scholar
• Denny, B.J., Wheelhouse, R.T., Stevens, M.F., Tsang, L.L. and Slack, J.A. (1994) "NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA", Biochemistry, 33, 9045–9051.
   Google Scholar
• Armstrong, M.J. and Galloway, S.M. (1997) "Mismatch repair provokes chromosome aberrations in hamster cells treated with methylating agents or 6-thioguanine, but not with ethylating agents", Mutat. Res., 373, 167 — 178.
   Google Scholar
• Hickman, M.J. and Samson, L.D. (1999) "Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents", PNAS, 96, 10764— 10769.
   Google Scholar
• Pegg, A.E. (2000) "Repair of 06-alkylguanine by alkyltransferases", Mutat. Res., 462, 83–100.
   Google Scholar
• Taverna, P., Catapano, C.V., Citti, L., Bonfanti, M. and D'Incalci, M. (1992) "Influence of 06-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosureas", Anti-Cancer Drugs, 3, 401–405.
   Web of Science ®Google Scholar
• Graziani, G., Faraoni, I., Grohmann, U., Bianchi, R., Binaglia, L., Margison, G.P., etal. (1995) 06-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immuno-genicity in murine L1210 leukemia", Cancer Res., 55, 6231 —6236.
   Google Scholar
• Tentori, L., Orlando, L. and Lacal, P.M. (1997) "Inhibition of 06-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymer-ase increases susceptibility of leukemic cells to apoptosis induced by temozolomide", Mol. Pharmacol., 52, 249 — 258.
   Web of Science ®Google Scholar
• D'Atri, S., Piccioni, D., Castellano, A., Tuorto, V., Franchi, A., Lu, K., et al. (1995) "Chemosensitivity to triazene compounds and 06-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukemic patients", Ann. Oncol., 6, 389 — 393.
   Google Scholar
• Pepponi, R., Marra, G., Fuggetta, M.P., Falcinelli, S., Pagani, E., Bonmassar, E., et al. (2003) "The effect of 06-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethy1)1 - nitrosourea, and cisplatin", J. Pharmacol. Exp. Ther., 304, 661 — 668.
   PubMed Web of Science ®Google Scholar
• Middlemas, D.S., Stewart, C.F., Kirstein, M.N., Poquette, C., Friedman, H.S., Houghton, P.J., et al. (2000) "Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models", Clin. Cancer Res., 6, 998 — 1007.
   Web of Science ®Google Scholar
• Sheikhha, M.H., Tobal, K. and Liu Yin, J.A. (2002) "High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome", Br. J. Haematol., 117, 359— 365.
   Google Scholar
• Zhu, Y.M., Das-Gupta, E.P. and Russell, N.H. (1999) "Micro-satellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia", Blood, 94, 733–740.
   PubMed Web of Science ®Google Scholar
• Pepponi, R., Graziani, G., Falcinelli, S., Vernole, P., Levati, L., Lacal, P.M., et al. (2001) "hMSH3 overexpression and cellular response to cytotoxic anticancer agents", Carcinogenesis, 22, 1131 — 1137.
   Google Scholar
• Krskova-Honzatkova, L., Cermak, J., Sajdova, J., Stary, J., Sedlacek, P. and Sieglova, Z. (2002) "Microsatellite instability in hematological malignancies", Leuk. Lymphoma, 43, 1979— 1986.
   Web of Science ®Google Scholar
• Inokuchi, K., Ikejima, M., Watanabe, A., Nakajima, E., Orimo, H., Nomura, T., etal. (1995) "Loss of expression of the human MSH3 gene in hematological malignancies", Biochem. Biophys. Res. Commun., 214, 171–179.
   PubMed Web of Science ®Google Scholar